Sangamo Therapeutics’ (SGMO) “Buy” Rating Reiterated at HC Wainwright

HC Wainwright reaffirmed their buy rating on shares of Sangamo Therapeutics (NASDAQ:SGMO) in a research report report published on Tuesday morning, Marketbeat reports. They currently have a $10.00 target price on the biopharmaceutical company’s stock.

SGMO has been the topic of a number of other reports. StockNews.com lowered Sangamo Therapeutics from a “buy” rating to a “hold” rating in a research note on Friday, December 6th. Barclays lifted their price target on Sangamo Therapeutics from $3.00 to $9.00 and gave the stock an “overweight” rating in a research report on Thursday, November 14th.

Sangamo Therapeutics Stock Down 1.5 %

Shares of SGMO stock opened at $1.91 on Tuesday. Sangamo Therapeutics has a 12 month low of $0.30 and a 12 month high of $3.18. The company has a market cap of $398.52 million, a PE ratio of -2.55 and a beta of 1.15. The business’s 50 day moving average is $1.78 and its two-hundred day moving average is $1.06.

Sangamo Therapeutics (NASDAQ:SGMO) last posted its earnings results on Tuesday, November 12th. The biopharmaceutical company reported $0.04 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of ($0.03) by $0.07. The business had revenue of $49.41 million for the quarter, compared to analyst estimates of $26.55 million. Sangamo Therapeutics had a negative net margin of 257.87% and a negative return on equity of 264.16%. During the same period last year, the business posted ($0.34) EPS. As a group, equities analysts expect that Sangamo Therapeutics will post -0.46 EPS for the current fiscal year.

Institutional Investors Weigh In On Sangamo Therapeutics

Hedge funds have recently made changes to their positions in the stock. Cubist Systematic Strategies LLC acquired a new position in Sangamo Therapeutics in the 2nd quarter valued at approximately $67,000. Meritage Portfolio Management increased its position in shares of Sangamo Therapeutics by 8.6% during the third quarter. Meritage Portfolio Management now owns 85,000 shares of the biopharmaceutical company’s stock valued at $74,000 after purchasing an additional 6,740 shares during the period. Point72 Asia Singapore Pte. Ltd. acquired a new position in shares of Sangamo Therapeutics in the second quarter valued at $89,000. XTX Topco Ltd lifted its position in Sangamo Therapeutics by 167.8% in the third quarter. XTX Topco Ltd now owns 103,716 shares of the biopharmaceutical company’s stock worth $90,000 after purchasing an additional 64,981 shares during the period. Finally, Wealth Enhancement Advisory Services LLC boosted its stake in Sangamo Therapeutics by 55.4% during the third quarter. Wealth Enhancement Advisory Services LLC now owns 108,945 shares of the biopharmaceutical company’s stock worth $94,000 after buying an additional 38,850 shares in the last quarter. Institutional investors own 56.93% of the company’s stock.

Sangamo Therapeutics Company Profile

Sangamo Therapeutics, Inc, a clinical-stage genomic medicine company, focuses on translating science into medicines that transform the lives of patients and families afflicted with serious diseases in the United States. The company's clinical-stage product candidates are ST-920, a gene therapy product candidate, which is in Phase 1/2 clinical study for the treatment of Fabry disease; TX200, a chimeric antigen receptor engineered regulatory T cell (CAR-Treg) therapy product candidate that is in Phase 1/2 clinical study for the prevention of immune-mediated rejection in HLA-A2 mismatched kidney transplantation; SB-525, a gene therapy product candidate, which is in Phase 3 clinical trial for the treatment of moderately severe to severe hemophilia A; BIVV003, a zinc finger nuclease gene-edited cell therapy product candidate that is in Phase 1/2 PRECIZN-1 clinical study for the treatment of sickle cell disease.